Staphylococcal Infections Clinical Trial
— StaphTypeOfficial title:
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections
Verified date | November 2016 |
Source | BG Unfallklinik |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Observational |
This was a prospective study performed between November 2011 and September 2013. Patients
with a confirmed S. aureus infection after fracture fixation or prosthetic joint infection
were included. Exclusion criteria included infections involving external fixation pins,
infections without any implanted hardware and culture positive patients not displaying any
clinical sign of infection. The following surgical parameters were documented: affected bone
or joint; type of implant; time between implantation of the device and onset of symptoms.
Personal characteristics and patients`health status were also documented. Any revision
surgeries involving the site of interest and all isolated pathogens were recorded throughout
the course of treatment and follow-up.
A follow up examination was performed an average of 23 months after discharge. Primary
outcome at follow up was cure. Cure was defined by the authors as: missing local (at site of
interest) or systemic signs of infection, terminated surgical and systemic therapy and
restoration of joint or limb function.
At the first surgical procedure after enrolment, at least four deep bone biopsies were taken
from the interface between implant and affected bone. Identification and antibiotic
susceptibility testing of all growth was performed. Multi-drug-resistance (MDR) was defined
according to the definitions of the European Committee of Antimicrobial Susceptibility
Testing (EUCAST). Biofilm formation was analysed and quantified in microtitre plate assays
according to protocol of Stepanovic et al.(see references).
Status | Completed |
Enrollment | 126 |
Est. completion date | March 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Infections after fracture fixation or prosthetic joint surgery - Affected bone or joint: Long bones of the lower and upper extremity - Bacterial growth of S. aureus at the site of interest - Written consent - Age: 18 and older Exclusion Criteria: - no prove of bacterial growth at site of interest - missing consent - infections involving external fixation pins, infections without any implanted hardware. |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
BG Unfallklinik | AO Research Institute Davos/ Switzerland |
Post V, Wahl P, Uçkay I, Ochsner P, Zimmerli W, Corvec S, Loiez C, Richards RG, Moriarty TF. Phenotypic and genotypic characterisation of Staphylococcus aureus causing musculoskeletal infections. Int J Med Microbiol. 2014 Jul;304(5-6):565-76. doi: 10.1016/j.ijmm.2014.03.003. — View Citation
Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, Ruzicka F. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007 Aug;115(8):891-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cure | Cure was defined by the authors as: missing local (at site of interest) or systemic signs of infection and terminated surgical and systemic antibiotic therapy. All Parameters had to be positive to fulfill the outcome parameter "cure".If one of the mentioned parameters was negative, outcome was defined as "not cured". Local signs of infection were defined as the appearance of: redness, tenderness, swelling or persisting wound drainage. | 23 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
Recruiting |
NCT00518076 -
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
|
N/A | |
Completed |
NCT01324440 -
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
|
Phase 1 | |
Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00063089 -
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
|
Phase 1/Phase 2 | |
Completed |
NCT00175370 -
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
|
N/A | |
Recruiting |
NCT03456544 -
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
|
||
Completed |
NCT02557568 -
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne
|
N/A | |
Terminated |
NCT01196169 -
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
|
Phase 4 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT02640937 -
Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections
|
N/A | |
Completed |
NCT00303069 -
V710 First-In-Man (FIM) Study (V710-001)
|
Phase 1 | |
Completed |
NCT00156377 -
Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
|
Phase 4 | |
Completed |
NCT00631566 -
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
|
N/A | |
Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
Completed |
NCT02782078 -
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
|
N/A | |
Completed |
NCT00859677 -
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
|
||
Completed |
NCT00211900 -
Evaluation of Manufacturing Lot of StaphVAX
|
Phase 3 | |
Completed |
NCT02492958 -
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
|
Phase 2 |